Inverse Effect of Fluoxetine on Medial Prefrontal Cortex Activation during Reward Reversal in ADHD and Autism

Cerebral Cortex

Volumn 25, Issue 7, 2015, Pages 1757-1770

  Chantiluke, Kaylita ^a   Barrett, Nadia ^b   Giampietro, Vincent ^a   Brammer, Michael ^a   Simmons, Andrew ^a,b   Murphy, Declan G ^a   Rubia, Katya ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

ADHD; ASD; cognitive flexibility; fMRI; serotonin

Indexed keywords

FLUOXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG EFFECT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; LEARNING; MALE; MEDIAL PREFRONTAL CORTEX; PRECUNEUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REWARD; TASK PERFORMANCE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; BRAIN MAPPING; DRUG EFFECTS; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; BRAIN MAPPING; CHILD; DOUBLE-BLIND METHOD; FLUOXETINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; PREFRONTAL CORTEX; REVERSAL LEARNING; REWARD; SEROTONIN UPTAKE INHIBITORS;

EID: 84936791316     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bht365     Document Type: Article

References (153)

1. Amaral DG, Schumann CM, Nordahl CW. 2008. Neuroanatomy of autism. Trends Neurosci. 31:137-145.
2. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders. Washington (DC): American Psychiatric Press.
3. Ashby FG, Isen AM. 1999. A neuropsychological theory of positive affect and its influence on cognition. Psychol Rev. 106:529.
4. Banerjee E, Banerjee D, Chatterjee A, Sinha S, Nandagopal K. 2012. Selective maternal inheritance of risk alleles and genetic interaction between serotonin receptor-1B (5-HTR1B) and serotonin transporter (SLC6A4) in ADHD. Psychiatry Res. 200:1083-1085.
5. Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M. 1991. Treatment of ADHD with Fluoxetine-a preliminary trial. J Am Acad Child Adolesc Psychiatry. 30:762-767.
6. Bird G, Silani G, Brindley R, White S, Frith U, Singer T. 2010. Empathic brain responses in insula are modulated by levels of alexithymia but not autism. Brain. 133:1515-1525.
7. Bonilha L, Cendes F, Rorden C, Eckert M, Dalgalarrondo P, Li LM, Steiner CE. 2008. Gray and white matter imbalance-typical structural abnormality underlying classic autism? Brain Dev. 30:396-401.
8. Boulougouris V, Glennon JC, Robbins TW. 2007. Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology. 33:2007-2019.
9. Brammer MJ, Bullmore ET, Simmons A, Williams SCR, Grasby PM, Howard RJ, Woodruff PWR, RabeHesketh S. 1997. Generic brain activation mapping in functional magnetic resonance imaging: a nonparametric approach. Magn Reson Imaging. 15:763-770.
10. Bridgett DJ, Walker ME. 2006. Intellectual functioning in adults with ADHD: a meta-analytic examination of full scale IQ differences between adults with and without ADHD. Psychol Assess. 18:1.
11. Buchsbaum MS, Hollander E, Haznedar MM, Tang C, Spiegel-Cohen J, Wei TC, Solimando A, Buchsbaum BR, Robins D, Bienstock C et al. 2001. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol. 4:119-125.
12. Bullmore E, Brammer M, Rabe-Hesketh S, Curtis V, Morris R, Williams S, Sharma T, McGuire P. 1999. Methods for diagnosis and treatment of stimulus-correlated motion in generic brain activation studies using fMRI. Hum Brain Mapp. 7:38-48.
13. Bullmore E, Long C, Suckling J, Fadili J, Calvert G, Zelaya F, Carpenter TA, Brammer M. 2001. Colored noise and computational inference in neurophysiological (fMRI) time series analysis: resampling methods in time and wavelet domains. Hum Brain Mapp. 12:61-78.
14. Bullmore ET, Suckling J, Overmeyer S, Rabe-Hesketh S, Taylor E, Brammer MJ. 1999. Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Trans Med Imaging. 18:32-42.
15. Carrasco M, Volkmar FR, Bloch MH. 2012. Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: evidence of publication bias. Pediatrics. 129:1301-1310.
16. Castellanos FX, Elia J, Kruesi MJP, Gulotta CS, Mefford IN, Potte WZ, Ritchie GF, Rapoport JL. 1994. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. Psychiatry Res. 52:305-316.
17. Cauda F, Geda E, Sacco K, D'Agata F, Duca S, Geminiani G, Keller R. 2011. Grey matter abnormality in autism spectrum disorder: an activation likelihood estimation meta-analysis study. J Neurol Neurosurg Psychiatry. 82:1304-1313.
18. Christakou A, Brammer M, Giampietro V, Rubia K. 2009. Right ventromedial and dorsolateral prefrontal cortices mediate adaptive decisions under ambiguity by integrating choice utility and outcome evaluation. J Neurosci. 29:11020-11028.
19. Christakou A, Gershman A, Brammer M, Rubia K. 2013. Neural and psychological maturation of decision-making in adolescence and young adulthood. J Cogn Neurosci. 25(11):807-1823.
20. Christakou A, Halari R, Smith AB, Ifkovits E, Brammer M, Rubia K. 2009. Sex-dependent age modulation of frontostriatal and temporo-parietal activation during cognitive control. Neuroimage. 48:223-236.
21. Chugani DC, Muzik O, Behen M, Rothermel R, Janisse JJ, Lee J, Chugani HT. 1999. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol. 45:287-295.
22. Chugani DC, Muzik O, Rothermel R, Behen M, Chakraborty P, Mangner T, daSilva EA, Chugani HT. 1997. Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol. 42:666-669.
23. Cohen MX, Elger CE, Weber B. 2008. Amygdala tractography predicts functional connectivity and learning during feedback-guided decision-making. Neuroimage. 39:1396-1407.
24. Conners CK, Sitarenios G, Parker JDA, Epstein JN. 1998. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 26:257-268.
25. Cools R, Clark L, Owen AM, Robbins TW. 2002. Defining the neural mechanisms of probabilistic reversal learning using eventrelated functional magnetic resonance imaging. J Neurosci. 22: 4563-4567.
26. Corbett BA, Constantine LJ, Hendren R, Rocke D, Ozonoff S. 2009. Examining executive functioning in children with autism spectrum disorder, attention deficit hyperactivity disorder and typical development. Psychiatry Res. 166:210-222.
27. Courchesne E, Campbell K, Solso S. 2011. Brain growth across the life span in autism: age-specific changes in anatomical pathology. Brain Res. 1380:138-145.
28. Courchesne E, Karns CM, Davis HR, Ziccardi R, Carper RA, Tigue ZD, Chisum HJ, Moses P, Pierce K, Lord C et al. 2001. Unusual brain growth patterns in early life in patients with autistic disorder-an MRI study. Neurology. 57:245-254.
29. Dalley JW, Mar AC, Economidou D, Robbins TW. 2008. Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry. Pharmacol Biochem Behav. 90:250-260.
30. Dalley JW, Roiser JP. 2012. Dopamine, serotonin and impulsivity. Neuroscience. 215:42-58.
31. Dalley JW, Theobald DE, Eagle DM, Passetti F, Robbins TW. 2002. Deficits in impulse control associated with tonically-elevated function in rat serotonergic prefrontal cortex. Neuropsychopharmacology. 26:716-728.
32. del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. 2011. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry. 69:145-157.
33. DeLong GR, Ritch CR, Burch S. 2002. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol. 44:652-659.
34. DeLong GR, Teague LA, Kamran MM. 1998. Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol. 40:551-562.
35. Dennis M, Francis DJ, Cirino PT, Schachar R, Barnes MA, Fletcher JM. 2009. Why IQ is not a covariate in cognitive studies of neurodevelopmental disorders. J Int Neuropsychol Soc. 15:331-343.
36. Derrfuss J, Brass M, Neumann J, von Cramon DY. 2005. Involvement of the inferior frontal junction in cognitive control: meta-analyses of switching and Stroop studies. Hum Brain Mapp. 25:22-34.
37. Dichter GS, Sikich L, Mahorney S, Felder JN, Lam KS, Turner-Brown L, Bodfish J. 2010. fMRI tracks reductions in repetitive behaviors in autism: two case studies. Neurocase. 16:307-316.
38. Di Martino A, Ross K, Uddin LQ, Sklar AB, Castellanos FX, Milham MP. 2009. Functional brain correlates of social and nonsocial processes in autism spectrum disorders: an activation likelihood estimation meta-analysis. Biol Psychiatry. 65:63-74.
39. Di Matteo V, Di Giovanni G, Pierucci M, Esposito E. 2008. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Prog Brain Res. 172:7-44.
40. Di Pietro NC, Seamans JK. 2011. Dopamine and serotonin interactively modulate prefrontal cortex neurons in vitro. Biol Psychiatry. 69:1204-1211.
41. Dodds CM, Mueller U, Clark L, van Loon A, Cools R, Robbins TW. 2008. Methylphenidate has differential effects on blood oxygenation level-dependent signal related to cognitive subprocesses of reversal learning. J Neurosci. 28:5976-5982.
42. Ebisch SJH, Gallese V, Willems RM, Mantini D, Groen WB, Romani GL, Buitelaar JK, Bekkering H. 2011. Altered intrinsic functional connectivity of anterior and posterior insula regions in highfunctioning participants with autism spectrum disorder. Hum Brain Mapp. 32:1013-1028.
43. Euston David R, Gruber Aaron J, McNaughton Bruce L. 2012. The role of medial prefrontal cortex in memory and decision making. Neuron. 76:1057-1070.
44. Evers EAT, Cools R, Clark L, van der Veen FM, Jolles J, Sahakian BJ, Robbins TW. 2005. Serotonergic modulation of prefrontal cortex during negative feedback in probabilistic reversal learning. Neuropsychopharmacology. 30:1138-1147.
45. Fatemi SH, Realmuto GM, Khan L, Thuras P. 1998. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord. 28:303-307.
46. Findling RL. 1996. Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol. 6:165-175.
47. Finger EC, Marsh AA, Mitchell DG, Reid ME, Sims C, Budhani S, Kosson DS, Chen G, Towbin KE, Leibenluft E et al. 2008. Abnormal ventromedial prefrontal cortex function in children with psychopathic traits during reversal learning. Arch Gen Psychiatry. 65:586-594.
48. Freyer T, Valerius G, Kuelz AK, Speck O, Glauche V, Hull M, Voderholzer U. 2009. Test-retest reliability of event-related functional MRI in a probabilistic reversal learning task. Psychiatry Res. 174:40-46.
49. Gadow KD, DeVincent CJ, Siegal VI, Olvet DM, Kibria S, Kirsch SF, Hatchwell E. 2013. Allele-specific associations of 5-HTTLPR/ rs25531 with ADHD and autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry. 40:292-297.
50. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. 1999. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science. 283:397-401.
51. Gammon GD, Brown TE. 1993. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol. 3:1-10.
52. Ghahremani DG, Monterosso J, Jentsch JD, Bilder RM, Poldrack RA. 2010. Neural components underlying behavioral flexibility in human reversal learning. Cereb Cortex. 20:1843-1852.
53. Gizer IR, Ficks C, Waldman ID. 2009. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 126:51-90.
54. Goldberg D, Murray R. 2002. Maudsley Handbook of Practical Psychiatry. New York: Oxford.
55. Goldman-Rakic PS. 1999. The "Psychic" neuron of the cerebral cortex. Ann N Y Acad Sci. 868:13-26.
56. Goldman-Rakic PS, Cools AR, Srivastava K. 1996. The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Philos Trans R Soc Lond Ser B Biol Sci. 351:1445-1453.
57. Goodman R, Scott S. 1999. Comparing the strengths and difficulties questionnaire and the child behavior checklist: is small beautiful? J Abnorm Child Psychol. 27:17-24.
58. Haber SN, Calzavara R. 2009. The cortico-basal ganglia integrative network: the role of the thalamus. Brain Res Bull. 78:69-74.
59. Hart H, Radua J, Mataix-Cols D, Rubia K. 2012. Meta-analysis of fMRI studies of timing in attention-deficit hyperactivity disorder (ADHD). Neurosci Biobehav Rev. 36:2248-2256.
60. Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K. 2013. Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring taskspecific, stimulant medication, and age effects. JAMA Psychiatr. 70:185-198.
61. Hill EL. 2004. Executive dysfunction in autism. Trends Cogn Sci. 8:26-32.
62. Hinz M, Stein A, Neff R, Weinberg R, Uncini T. 2011. Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation. Neuropsychiatr Dis Treat. 7:31-38.
63. Hollander E, Phillips A, ChaplinW, Zagursky K, Novotny S, Wasserman S, Iyengar R. 2005. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 30:582-589.
64. Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, Wasserman S, Swanson E, Settipani C. 2012. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry. 169:292-299.
65. Hranilovic D, Bujas-Petkovic Z, Vragovic R, Vuk T, Hock K, Jernej B. 2007. Hyperserotonemia in adults with autistic disorder. J Autism Dev Disord. 37:1934-1940.
66. Huettel SA, Song AW, McCarthy G. 2005. Decisions under uncertainty: probabilistic context influences activation of prefrontal and parietal cortices. J Neurosci. 25:3304-3311.
67. Jacobs BL, Azmitia EC. 1992. Structure and function of the brain serotonergic system. Physiol Rev. 72:165-229.
68. Kana RK, Keller TA, Minshew NJ, Just MA. 2007. Inhibitory control in high-functioning autism: decreased activation and underconnectivity in inhibition networks. Biol Psychiatry. 62:198-206.
69. Kehagia AA, Murray GK, Robbins TW. 2010. Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation. Curr Opin Neurobiol. 20:199-204.
70. Konrad K, Eickhoff SB. 2010. Is the ADHD brain wired differently? A review on structural and functional connectivity in attention deficit hyperactivity disorder. Hum Brain Mapp. 31:904-916.
71. Kravitz DJ, Saleem KS, Baker CI, Mishkin M. 2011. A new neural framework for visuospatial processing. Nat Rev Neurosci. 12:217-230.
72. Langen M, Leemans A, Johnston P, Ecker C, Daly E, Murphy CM, dell'Acqua F, Durston S, Murphy DGM. 2012. Fronto-striatal circuitry and inhibitory control in autism: findings from diffusion tensor imaging tractography. Cortex. 48:183-193.
73. Liu X, Hairston J, Schrier M, Fan J. 2011. Common and distinct networks underlying reward valence and processing stages: a meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev. 35:1219-1236.
74. Loose R, Kaufmann C, Tucha O, Auer DP, Lange KW. 2006. Neural networks of response shifting: influence of task speed and stimulus material. Brain Res. 1090:146-155.
75. Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, DiLavore PC, Pickles A, Rutter M. 2000. The autism diagnostic observation schedule generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 30:205-223.
76. Lord C, Rutter M, Couteur A. 1994. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 24:659-685.
77. Makkonen I, Riikonen R, Kokki H, Airaksinen MM, Kuikka JT. 2008. Serotonin and dopamine transporter binding in children with autism determined by SPECT. Dev Med Child Neurol. 50:593-597.
78. McCoy A, Platt M. 2005. Expectations and outcomes: decision-making in the primate brain. J Compar Physiol A. 191:201-211.
79. McGough JJ, McCracken JT, Loo SK, Manganiello M, Leung MC, Tietjens JR, Trinh T, Baweja S, Suddath R, Smalley SL et al. 2009. A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 48:1155-1164.
80. Mitchell DGV, Luo Q, Avny SB, Kasprzycki T, Gupta K, Chen G, Finger EC, Blair RJR. 2009. Adapting to dynamic stimulus-response values: differential contributions of inferior frontal, dorsomedial, and dorsolateral regions of prefrontal cortex to decision making. J Neurosci. 29:10827-10834.
81. Mitchell DGV, Rhodes RA, Pine DS, Blair RJR. 2008. The contribution of ventrolateral and dorsolateral prefrontal cortex to response reversal. Behav Brain Res. 187:80-87.
82. Mulder EJ, Anderson GM, Kema IP, de Bildt A, van Lang NDJ, den Boer JA, Minderaa RB. 2004. Platelet serotonin levels in pervasive developmental disorders and mental retardation: diagnostic group differences, within-group distribution, and behavioral correlates. J Am Acad Child Adolesc Psychiatry. 43:491-499.
83. Murano M, Saitow F, Suzuki H. 2011. Modulatory effects of serotonin on glutamatergic synaptic transmission and long-term depression in the deep cerebellar nuclei. Neuroscience. 172:118-128.
84. Murphy DGM, Daly E, Schmitz N, Toal F, Murphy K, Curran S, Erlandsson K, Eersels J, Kerwin R, Ell P et al. 2006. Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study. Am J Psychiatry. 163:934-936.
85. Murphy FC, Smith KA, Cowen PJ, Robbins TW, Sahakian BJ. 2002. The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. Psychopharmacology (Berl). 163:42-53.
86. Nakamura K, Sekine Y, Ouchi Y, Tsujii M, Yoshikawa E, Futatsubashi M, Tsuchiya KJ, Sugihara G, Iwata Y, Suzuki K et al. 2010. Brain serotonin and dopamine transporter bindings in adults with highfunctioning autism. Arch Gen Psychiatry. 67:59-68.
87. Nakao T, Radua Q, Rubia K, Mataix D. 2011. Gray matter volume abnormalities in ADHD and the effects of stimulant medication: voxelbased meta-analysis. Am J Psychiatry. 168(11):1154-1163.
88. Oades RD. 2007. Role of the serotonin system in ADHD: treatment implications. Expert Rev Neurother. 7:1357-1374.
89. Oades RD, Daniels R, Rascher W. 1998. Plasma neuropeptide-Y levels, monoamine metabolism, electrolyte excretion and drinking behavior in children with attention-deficit hyperactivity disorder. Psychiatry Res. 80:177-186.
90. O'Doherty J, Critchley H, Deichmann R, Dolan RJ. 2003. Dissociating valence of outcome from behavioral control in human orbital and ventral prefrontal cortices. J Neurosci. 23:7931-7939.
91. O'Doherty J, Kringelbach ML, Rolls ET, Hornak J, Andrews C. 2001. Abstract reward and punishment representations in the human orbitofrontal cortex. Nat Neurosci. 4:95-102.
92. Oldfield RC. 1971. The assessment and analysis of handedness: The Edinburgh inventory. Neuropsychologia. 9:97-113.
93. Packard MG, Knowlton BJ. 2002. Learning and memory functions of the basal ganglia. Annu Rev Neurosci. 25:563-593.
94. Pardini M, Elia M, Garaci F, Guida S, Coniglione F, Krueger F, Benassi F, Emberti Gialloreti L. 2012. Long-term cognitive and behavioral therapies, combined with augmentative communication, are related to uncinate fasciculus integrity in autism. J Autism Dev Disord. 42:585-592.
95. Paulus MP, Stein MB. 2006. An insular view of anxiety. Biol Psychiatry. 60:383-387.
96. Philip RCM, Dauvermann MR, Whalley HC, Baynham K, Lawrie SM, Stanfield AC. 2012. A systematic review and meta-analysis of the fMRI investigation of autism spectrum disorders. Neurosci Biobehav Rev. 36:901-942.
97. Piven J, Tsai G, Nehme E, Coyle JT, Chase GA, Folstein SE. 1991. Platelet serotonin: a possible marker for familial autism. J Autism Dev Disord. 21:51-59.
98. Poustka L, Jennen-Steinmetz C, Henze R, Vomstein K, Haffner J, Sieltjes B. 2012. Fronto-temporal disconnectivity and symptom severity in children with autism spectrum disorder. World J Biol Psychiatry. 13:269-280.
99. Quintana H, Butterbaugh GJ, Purnell W, Layman AK. 2007. Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents. Child Psychiatry Hum Dev. 37:241-253.
100. Radua J, Via E, Catani M, Mataix-Cols D. 2011. Voxel-based metaanalysis of regional white-matter volume differences in autism spectrum disorder versus healthy controls. Psychol Med. 41:1539-1550.
101. Rao PA, Landa RJ. 2013. Association between severity of behavioral phenotype and comorbid attention deficit hyperactivity disorder symptoms in children with autism spectrum disorders. Autism. 0:1-9.
102. Ravizza SM, Carter CS. 2008. Shifting set about task switching: behavioral and neural evidence for distinct forms of cognitive flexibility. Neuropsychologia. 46:2924-2935.
103. Remijnse PL, Nielen MMA, Uylings HBM, Veltman DJ. 2005. Neural correlates of a reversal learning task with an affectively neutral baseline: an event-related fMRI study. Neuroimage. 26:609-618.
104. Ridderinkhof KR, Ullsperger M, Crone EA, Nieuwenhuiss S. 2004. The role of the medial frontal cortex in cognitive control. Science. 306:443-447.
105. Roberts AC. 2011. The importance of serotonin for orbitofrontal function. Biol Psychiatry. 69:1185-1191.
106. Rommelse NNJ, Franke B, Geurts HM, Hartman CA, Buitelaar JK. 2010. Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder. Eur Child Adolesc Psychiatry. 19:281-295.
107. Rommelse NNJ, Geurts HM, Franke B, Buitelaar JK, Hartman CA. 2011. A review on cognitive and brain endophenotypes that may be common in autism spectrum disorder and attention-deficit/hyperactivity disorder and facilitate the search for pleiotropic genes. Neurosci Biobehav Rev. 35:1363-1396.
108. Rubia K. 2011. "Cool" inferior frontostriatal dysfunction in attentiondeficit/ hyperactivity disorder versus "hot" ventromedial orbitofrontallimbic dysfunction in conduct disorder: a review. Biol Psychiatry. 69:69-87.
109. Rubia K, Alzamora A, Smith ABS, Cubillo A, Brammer M, Radua Q. Forthcoming 2013. Effects of stimulants on brain function in ADHD: a systematic review and meta-analysis. Biol Psych.; http:// dx. doi. org/10. 1016/j. biopsych. 2013. 10. 016
110. Rubia K, Cubillo A, Smith AB, Woolley J, Heyman I, Brammer MJ. 2010. Disorder-specific dysfunction in right inferior prefrontal cortex during two inhibition tasks in boys with attention-deficit hyperactivity disorder compared to boys with obsessive-compulsive disorder. Hum Brain Mapp. 31:287-299.
111. Rubia K, Halari R, Cubillo A, Mohammad AM, Scott S, Brammer M. 2010. Disorder?specific inferior prefrontal hypofunction in boys with pure attention?deficit/hyperactivity disorder compared to boys with pure conduct disorder during cognitive flexibility. Hum Brain Mapp. 31:1823-1833.
112. Rubia K, Halari R, Mohammad A-M, Taylor E, Brammer M. 2011. Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder. Biol Psychiatry. 70:255-262.
113. Rubia K, Overmeyer S, Taylor E, Brammer M, Williams SCR, Simmons A, Bullmore ET. 1999. Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry. 156:891-896.
114. Rubia K, Smith AB, Brammer MJ, Taylor E. 2003. Right inferior prefrontal cortex mediates response inhibition while mesial prefrontal cortex is responsible for error detection. Neuroimage. 20: 351-358.
115. Rubia K, Smith AB, Brammer MJ, Toone B, Taylor E. 2005. Abnormal brain activation during inhibition and error detection in medicationnaive adolescents with ADHD. AmJ Psychiatry. 162:1067-1075.
116. Rubia K, Smith AB, Halari R, Matsukura F, Mohammad M, Taylor E, Brammer MJ. 2009. Disorder-specific dissociation of orbitofrontal dysfunction in boys with pure conduct disorder during reward and ventrolateral prefrontal dysfunction in boys with pure ADHD during sustained attention. Am J Psychiatry. 166:83-94.
117. Rubia K, Smith AB, Taylor E, Brammer M. 2007. Linear age-correlated functional development of right inferior fronto-striato-cerebellar networks during response inhibition and anterior cingulate during error-related processes. Hum Brain Mapp. 28:1163-1177.
118. Rubia K, Smith AB, Woolley J, Nosarti C, Heyman I, Taylor E, Brammer M. 2006. Progressive increase of frontostriatal brain activation from childhood to adulthood during event-related tasks of cognitive control. Hum Brain Mapp. 27:973-993.
119. Rutter M, Bailey A, Lord C. 2003. The Social Communication Questionnaire: Manual. Los Angeles: Western Psychological Services.
120. Sanders J, Johnson KA, Garavan H, Gill M, Gallagher L. 2008. A review of neuropsychological and neuroimaging research in autistic spectrum disorders: attention, inhibition and cognitive flexibility. Res Autism Spectr Disord. 2:1-16.
121. Schmitz N, Rubia K, Daly E, Smith A, Williams S, Murphy DGM. 2006. Neural correlates of executive function in autistic spectrum disorders. Biol Psychiatry. 59:7-16.
122. Schmitz N, Rubia K, van Amelsvoort T, Daly E, Smith A, Murphy DGM. 2008. Neural correlates of reward in autism. Br J Psychiatry. 192:19-24.
123. Schweren LJS, de Zeeuw P, Durston S. 2012. MR imaging of the effects of methylphenidate on brain structure and function in attentiondeficit/ hyperactivity disorder. Euro Neuropsychopharm. 23: 1151-1164.
124. Shafritz KM, Dichter GS, Baranek GT, Belger A. 2008. The neural circuitry mediating shifts in behavioral response and cognitive set in autism. Biol Psychiatry. 63:974-980.
125. Shaw P, Eckstrand K, Sharp W, Blumenthal J, Lerch JP, Greenstein D, Clasen L, Evans A, Giedd J, Rapoport JL. 2007. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci USA. 104:19649-19654.
126. Shaw P, Gilliam M, Liverpool M, Weddle C, Malek M, Sharp W, Greenstein D, Evans A, Rapoport J, Giedd J. 2011. Cortical development in typically developing children with symptoms of hyperactivity and impulsivity: support for a dimensional view of attention deficit hyperactivity disorder. Am J Psychiatry. 168: 143-151.
127. Sibley D, Hanin I, Kuhar M, Skolnick P. 2007. Handbook of contemporary neuropharmacology. New York:Wiley Blackwell.
128. Simmons A, Moore E, Williams SCR. 1999. Quality control for functional magnetic resonance imaging using automated data analysis and Shewhart charting. Magn Reson Med. 41:1274-1278.
129. Simmons A, Strigo I, Matthews SC, Paulus MP, Stein MB. 2006. Anticipation of aversive visual stimuli is associated with increased insula activation in anxiety-prone subjects. Biol Psychiatry. 60: 402-409.
130. Sinzig J, Lehmkuhl G. 2007. What do we know about the serotonergic genetic heterogeneity in attention-deficit/hyperactivity and autistic disorders? Psychopathology. 40:329-337.
131. Small DM, Gitelman DR, Gregory MD, Nobre AC, Parrish TB, Mesulam MM. 2003. The posterior cingulate and medial prefrontal cortex mediate the anticipatory allocation of spatial attention. Neuroimage. 18:633-641.
132. Smith AB, Taylor E, Brammer M, Halari R, Rubia K. 2008. Reduced activation in right lateral prefrontal cortex and anterior cingulate gyrus in medication-naive adolescents with attention deficit hyperactivity disorder during time discrimination. J Child Psychol Psychiatry. 49:977-985.
133. Smith AB, Taylor E, Brammer M, Toone B, Rubia K. 2006. Task-specific hypoactivation in prefrontal and temporoparietal brain regions during motor inhibition and task switching in medication-naive children and adolescents with attention deficit hyperactivity disorder. Am J Psychiatry. 163:1044-1051.
134. Solomon M, Ozonoff SJ, Ursu S, Ravizza S, Cummings N, Ly S, Carter CS. 2009. The neural substrates of cognitive control deficits in autism spectrum disorders. Neuropsychologia. 47: 2515-2526.
135. Spivak B, Vered Y, Yoran-Hegesh R, Averbuch E, Mester R, Graf E, Weizman A. 1999. Circulatory levels of catecholamines, serotonin and lipids in attention deficit hyperactivity disorder. Acta Psychiatr Scand. 99:300-304.
136. Stigler KA, McDonald BC, Anand A, Saykin AJ, McDougle CJ. 2011. Structural and functional magnetic resonance imaging of autism spectrum disorders. Brain Res. 1380:146-161.
137. Talairach J, Tournoux P. 1988. Co-planar stereotaxic atlas of the human brain. New York: Thieme New York.
138. Thirion B, Pinel P, Meriaux S, Roche A, Dehaene S, Poline JB. 2007. Analysis of a large fMRI cohort: statistical and methodological issues for group analyses. Neuroimage. 35:105-120.
139. Uddin LQ, Menon V. 2009. The anterior insula in autism: underconnected and under-examined. Neurosci Biobehav Rev. 33: 1198.
140. van der Meer JMJ, Oerlemans AM, van Steijn DJ, Lappenschaar MGA, de Sonneville LMJ, Buitelaar JK, Rommelse NNJ. 2012. Are autism spectrum disorder and attention-deficit/hyperactivity disorder different manifestations of one overarching disorder? Cognitive and symptom evidence from a clinical and population-based sample. J Am Acad Child Adolesc Psychiatry. 51:1160-1172.
141. van Ewijk H, Heslenfeld DJ, Zwiers MP, Buitelaar JK, Oosterlaan J. 2012. Diffusion tensor imaging in attention deficit/hyperactivity disorder: a systematic review and meta-analysis. Neurosci Biobehav Rev. 36:1093-1106.
142. Varnäs K, Halldin C, Hall H. 2004. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp. 22:246-260.
143. Volkow ND, Wang G-J, Fowler JS, Gatley SJ, Logan J, Ding Y-S, Hitzemann R, Pappas N. 1998. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 155:1325-1331.
144. Wechsler D. 1999. Wechsler Abbreviated Scale of Intelligence. San Antonio (TX): The Psychological Corporation.
145. Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF. 2005. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry. 57:1336-1346.
146. Williams K, Wheeler DM, Silove N, Hazell P. 2010. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 8:1-26.
147. Wong DT, Bymaster FP, Engleman EA. 1995. Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 57:411-441.
148. World Health Organisation. 1994. ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidlines. Geneva:World Health Organisation.
149. Yerys BE, Wallace GL, Harrison B, Celano MJ, Giedd JN, Kenworthy LE. 2009. Set-shifting in children with autism spectrum disorders: reversal shifting deficits on the intradimensional/extradimensional shift test correlate with repetitive behaviors. Autism. 13: 523-538.
150. Yin HH, Knowlton BJ. 2006. The role of the basal ganglia in habit formation. Nat Rev Neurosci. 7:464-476.
151. Zafeiriou DI, Ververi A, Vargiami E. 2009. The serotonergic system: its role in pathogenesis and early developmental treatment of autism. Curr Neuropharmacol. 7:150-157.
152. Zepf FD, Gaber TJ, Baurmann D, Bubenzer S, Konrad K, Herpertz-Dahlmann B, Stadler C, Poustka F, Wockel L. 2010. Serotonergic neurotransmission and lapses of attention in children and adolescents with attention deficit hyperactivity disorder: availability of tryptophan influences attentional performance. Int J Neuropsychopharmacol. 13:933-941.
153. Zepf FD, Holtmann M, Stadler C, Demisch L, Schmitt M, Wockel L, Poustka F. 2008. Diminished serotonergic functioning in hostile children with ADHD: Tryptophan depletion increases behavioural inhibition. Pharmacopsychiatry. 41:60-65.